

REMARKS

This amendment and remarks are in response to the Office Action of August 8, 2006. Claims 1, 3-11, 13 and 15-40 were in the case, but are herein cancelled without prejudice. New Claims 41-65 are added and find their support in the provisional application number 60/419,791, to which the pending application claims priority. The new claims reflect amendments to conform with the existing restriction requirement (Group II) wherein R⁴ is R^c and the central ring containing Q¹ and Q² is piperazine.

35 U.S.C. § 112

New Claims 41-65 have been provided and Applicants believe that the full scope of these claims is supported by the large number of examples, some of which are present in Claim 65.

35 U.S.C. § 102(e)

The previous claim set was rejected as being anticipated by Sun. The 102(e) date for Sun is December 24, 2002. New Claims 41-65 come directly from the provisional filing in this case which has a priority date of October 17, 2002. Accordingly, Sun is removed as a reference from these claims.

35 U.S.C. § 103(a)


The previous claim set was rejected as being obvious in light of Sun. The 102(e) date for Sun is December 24, 2002. New Claims 41-65 come directly from the provisional filing in this case which has a priority date of October 17, 2002. Accordingly, Sun is removed as a reference from these claims.

Applicants' attorney sincerely and respectfully requests that the Examiner consider, a telephone (805-447-3299) or personal interview to resolve any outstanding issues deemed appropriate by the Examiner.

Please send all future correspondence to:

US Patent Operations/RVP
Dept. 4300, M/S 28-2-C
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

Respectfully submitted,



Richard V. Person
Attorney for Applicants
Registration No.: 42,991
Phone: (805) 447-3299
Date: January 10, 2007